Greater Potential Benefit In Overall Survival For Eribulin Compared With Capecitabine
 

Subgroup analyses from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate, with capecitabine, a standard chemotherapy medication in women with previously treated metastatic breast cancer, showed increased benefit among women sharing certain traits...

More...